Lilly Insulin Glargine Versus Lantus((R)) in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study

Mohan, V; Ahn, KJ; Cho, YM; Sahay, RK; Huang, CN; Kalra, S; Chadha, M; Bhattacharya, I; Kim, SY; Spaepen, E

Bhattacharya, I (reprint author), Eli Lilly & Co India Pvt Ltd, Inst Area, Plot 92,Sect 32, Gurgaon 122001, Haryana, India.

CLINICAL DRUG INVESTIGATION, 2019; 39 (8): 745

Abstract

Background and ObjectivesLilly insulin glargine (LY IGlar; Basaglar((R))) and the reference insulin glargine product (IGlar; Lantus((R))) are basal in......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索